Chief Medical Officer, Xalud Therapeutics
Stephen Collins, MD, PhD‘s career has focused on the research and clinical development of therapeutics for a broad range of disorders.
Currently he serves on the boards of several biotechnology companies. In addition to his Chairmanship of Xalud Therapeutics he serves as President and CEO of Biscayne Pharmaceuticals a company specializing in the development of severe, life-threatening neurologic diseases. Previously he was the President and CEO of NeuroTherapeutics Pharma, an early stage biotechnology company. Prior to NeuroTherapeutics Pharma, he was Chief Scientific Officer & VP for Clinical Affairs of Ovation Pharmaceuticals, an oncology and CNS-focused biopharmaceutical company acquired by Lundbeck A/S for $963M. Dr. Collins joined Ovation in 2003, shortly after its formation and was responsible for establishing the company’s R&D group and growing it into a team of over 60 professionals. His R&D team performed the preclinical and clinical activities for four development programs of Ovation, which resulted in two approved NDAs, two programs in global Phase III clinical trials, one program in Phase II clinical trials, multiple INDs, and life-cycle management projects for the firm’s marketed assets. Prior to Ovation, Dr. Collins was a Global Director at Johnson & Johnson, overseeing the early-stage development of a variety of agents. He was also a member of the global in-licensing advisory team. Prior to Johnson and Johnson, he worked in Abbott Laboratories’ Pharmaceutical and Hospital Products Divisions. While there, he developed drugs for multiple indications and was responsible for the preclinical and clinical programs that supported the successful filing and approval of multiple NDA and sNDA submissions.
Previous to his industry experience, Dr. Collins was on the faculty of medicine at both Case Western Reserve University and the University of California-San Francisco. Dr. Collins earned his MD and PhD at Case Western Reserve University and performed his undergraduate studies in Physics at the University of California, Berkeley.